Literature DB >> 16613351

NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.

Hiep Phuc Dong1, Mari Bunkholt Elstrand, Arild Holth, Ilvars Silins, Aasmund Berner, Claes G Trope, Ben Davidson, Björn Risberg.   

Abstract

We studied the clinical role of leukocyte infiltration and chemokine receptor expression in ovarian carcinoma effusions. Expression of leukocyte markers (CD3, CD4, CD8, CD4/CD8 ratio, CD16, CD19, and CD14) and chemokine receptors (CXCR1, CXCR4, CCR2, CCR5, and CCR7) was studied in 73 effusions by using flow cytometry. CXCR4, CCR5, and CCR7 were expressed abundantly on leukocytes, but all receptors were expressed rarely on cancer cells. The presence of natural killer cells (P = .042) and International Federation of Gynecology and Obstetrics (FIGO) stage IV disease (P = .024) predicted worse overall survival (OS). A higher percentage of CD19+ cells (P = .015) and stage IV disease (P = .008) predicted poor survival for patients with postchemotherapy effusions. Only FIGO stage retained significance as a predictor of OS (P = .035) in multivariate analysis. Chemokine receptors are expressed widely on leukocytes but rarely on carcinoma cells in ovarian carcinoma effusions, arguing against an autocrine chemokine pathway in this malignancy. Immune response parameters in ovarian cancer effusions are weak predictors of outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613351

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  55 in total

1.  High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator.

Authors:  Sveinung W Sorbye; Thomas Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 2.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

Review 3.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

Review 4.  Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.

Authors:  Eric R Craig; Angelina I Londoño; Lyse A Norian; Rebecca C Arend
Journal:  Gynecol Oncol       Date:  2016-10-15       Impact factor: 5.482

5.  Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.

Authors:  Monica Bodogai; Kanako Moritoh; Catalina Lee-Chang; Christine M Hollander; Cheryl A Sherman-Baust; Robert P Wersto; Yoshihiko Araki; Ichiro Miyoshi; Li Yang; Giorgio Trinchieri; Arya Biragyn
Journal:  Cancer Res       Date:  2015-07-16       Impact factor: 12.701

6.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.

Authors:  Marloes Gooden; Margit Lampen; Ekaterina S Jordanova; Ninke Leffers; J Baptist Trimbos; Sjoerd H van der Burg; Hans Nijman; Thorbald van Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

7.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

Review 8.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 9.  B cell regulation of anti-tumor immune response.

Authors:  Yu Zhang; Richard Morgan; Eckhard R Podack; Joseph Rosenblatt
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.